ACTEMRA® (tocilizumab)
ALECENSA® (alectinib)
Avastin® (bevacizumab)
COLUMVI™ (glofitamab-gxbm)
COTELLIC® (cobimetinib)
ENSPRYNG® (satralizumab-mwge)
Erivedge® (vismodegib)
Evrysdi® (risdiplam)
GAZYVA® (obinutuzumab)
HEMLIBRA® (emicizumab-kxwh)
Herceptin® (trastuzumab)
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
Itovebi™ (inavolisib)
KADCYLA® (ado-trastuzumab emtansine)
LUCENTIS® (ranibizumab injection)
LUNSUMIO™ (mosunetuzumab-axgb)
OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq)
PERJETA® (pertuzumab)
PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
PiaSky™ (crovalimab-akkz)
POLIVY® (polatuzumab vedotin-piiq)
Pulmozyme® (dornase alfa) Inhalation Solution
Rituxan® (rituximab) for Rheumatoid Arthritis (RA)
RITUXAN® (rituximab) for Oncology
Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
ROZLYTREK® (entrectinib)
SUSVIMO™ (ranibizumab injection)
TECENTRIQ® (atezolizumab)
TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
VABYSMO® (faricimab-svoa)
VENCLEXTA® (venetoclax tablets)
XOLAIR® (omalizumab) for subcutaneous use
ZELBORAF® (vemurafenib)
Oncology
Ophthalmology
Rheumatology
Genentech co-pay programs provide financial assistance to patients to help with their co-pays, co-insurance or other out-of-pocket costs. If eligible commercially insured patients need assistance with their out-of-pocket costs, the HEMLIBRA Co-pay Program may help.
To get started, call (844) HEM-COPAY/(844) 436-2672 or visit HEMLIBRACopay.com.
Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.
